Stifel analyst Laura Prendergast raised the firm’s price target on Tango Therapeutics (TNGX) to $24 from $15 and keeps a Buy rating on the shares. The firm views the “recent flurry of PRMT5 inhibitor + RAS(ON) combinations” to be de-risking for Tango’s first-line pancreatic ductal adenocarcinoma opportunity, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics price target raised to $19 from $15 at Wedbush
- Tango Therapeutics price target raised to $20 from $18 at Guggenheim
- Tango Therapeutics price target raised to $27 from $13 at H.C. Wainwright
- Midday Fly By: Stocks tumble as oil prices climb again
- Erasca, Tango Therapeutics enter clinical collaboration, supply agreement